Literature DB >> 15780988

Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice.

Atsushi Kumanogoh1, Takashi Shikina, Kazuhiro Suzuki, Satoshi Uematsu, Kazunori Yukawa, Shin-Ichiro Kashiwamura, Hiroko Tsutsui, Midori Yamamoto, Hyota Takamatsu, Elizabeth P Ko-Mitamura, Noriko Takegahara, Satoko Marukawa, Isao Ishida, Hiroshi Morishita, Durbaka V R Prasad, Manabu Tamura, Masayuki Mizui, Toshihiko Toyofuku, Shizuo Akira, Kiyoshi Takeda, Masaru Okabe, Hitoshi Kikutani.   

Abstract

The class IV semaphorin Sema4A provides a costimulatory signal to T cells. To investigate the possible developmental and regulatory roles of Sema4A in vivo, we generated Sema4A-deficient mice. Although Sema4A-deficient mice develop normally, DCs and T cells from knockout mice display poor allostimulatory activities and T helper cell (Th) differentiation, respectively. Interestingly, in addition to its expression on DCs, Sema4A is upregulated on Th1-differentiating cells, and it is necessary for in vitro Th1 differentiation and T-bet expression. Consequently, in vivo antigen-specific T cell priming and antibody responses against T cell-dependent antigens are impaired in the mutant mice. Additionally, Sema4A-deficient mice exhibit defective Th1 responses. Furthermore, reconstitution studies with antigen-pulsed DCs reveal that DC-derived Sema4A is important for T cell priming, while T cell-derived Sema4A is involved in developing Th1 responses. Collectively, these results indicate a nonredundant role of Sema4A not only in T cell priming, but also in the regulation of Th1/Th2 responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780988     DOI: 10.1016/j.immuni.2005.01.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  60 in total

Review 1.  Regulation of immune cell responses by semaphorins and their receptors.

Authors:  Hyota Takamatsu; Tatsusada Okuno; Atsushi Kumanogoh
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

2.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

Review 3.  Semaphorins: a new class of immunoregulatory molecules.

Authors:  Noriko Takegahara; Atsushi Kumanogoh; Hitoshi Kikutani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 4.  Immune regulation by the TIM gene family.

Authors:  Anjali J de Souza; Lawrence P Kane
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Semaphorin 4A Stabilizes Human Regulatory T Cell Phenotype via Plexin B1.

Authors:  Svetlana P Chapoval; Molly Hritzo; Xiulan Qi; Luca Tamagnone; Amit Golding; Achsah D Keegan
Journal:  Immunohorizons       Date:  2019-02

Review 6.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

Review 7.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

8.  Cell type-specific DNA methylation at intragenic CpG islands in the immune system.

Authors:  Aimée M Deaton; Shaun Webb; Alastair R W Kerr; Robert S Illingworth; Jacky Guy; Robert Andrews; Adrian Bird
Journal:  Genome Res       Date:  2011-05-31       Impact factor: 9.043

Review 9.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

Review 10.  The role of semaphorins in immune responses and autoimmune rheumatic diseases.

Authors:  Masayuki Nishide; Atsushi Kumanogoh
Journal:  Nat Rev Rheumatol       Date:  2017-12-07       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.